Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis [Yahoo! Finance]
Enlivex Therapeutics Ltd. - Ordinary Shares (ENLV)
Company Research
Source: Yahoo! Finance
immunotherapy company, today announced that the Israeli Ministry of Health authorized the initiation of an investigator-initiated Phase I trial to evaluate the safety, tolerability and initial efficacy of Allocetra™ for injection into the temporomandibular joint (TMJ) in patients suffering from TMJ osteoarthritis. The study will be conducted by the Rheumatology Unit at Sheba Medical Center in collaboration with the Department of Oral and Maxillofacial Surgery. Notably, Sheba Medical Center was recently ranked among the top 10 hospitals in the world by Newsweek Dr. Oren Hershkovitz, CEO of Enlivex, commented, “TMJ osteoarthritis is a unique disease that can affect young, otherwise healthy individuals, causing substantial pain and impairment in oral function. In many cases, existing therapies fail to provide long-term relief, forcing patients to undergo multiple surgeries as their disease progresses. Allocetra™ is currently being evaluated for other types of osteoarthritis and may p
Show less
Read more
Impact Snapshot
Event Time:
ENLV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ENLV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ENLV alerts
High impacting Enlivex Therapeutics Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
ENLV
News
- Enlivex Therapeutics Ltd. (NASDAQ: ENLV) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $13.00 price target on the stock.MarketBeat
- Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ OsteoarthritisGlobeNewswire
- Trump's crypto advocacy steers businesses away from traditional treasury assets [Yahoo! Finance Canada]Yahoo! Finance Canada
- Trump's crypto advocacy steers businesses away from traditional treasury assets [Yahoo! Finance Canada]Yahoo! Finance Canada
- Trump's crypto advocacy steers businesses away from traditional treasury assets [Yahoo! Finance]Yahoo! Finance
ENLV
Analyst Actions
- 9/27/24 - HC Wainwright
ENLV
Sec Filings
- 12/11/24 - Form 6-K
- 12/3/24 - Form 6-K
- 11/29/24 - Form 6-K
- ENLV's page on the SEC website